RECRUITING

SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.

Official Title

SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)

Quick Facts

Study Start:2023-04-03
Study Completion:2025-07-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05375643

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult (age 18 years or older)
  2. * Black, Latinx, OR older adult (age 70 years or older)
  3. * Scheduled for a new patient consultation
  4. * Suspected or confirmed advanced malignancy (requiring active treatment)
  5. * Gastrointestinal, hematologic, or thoracic cancer
  6. * DFCI patient at Longwood/Chestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley
  1. * Malignancy or former malignancy that requires only surveillance
  2. * Not continuing care at a participating DFCI site
  3. * Speaks a language other than English or Spanish
  4. * Unable to provide consent

Contacts and Locations

Study Contact

Nadine J McCleary, MD MPH
CONTACT
(617) 632-6729
nj_mccleary@dfci.harvard.edu
Nadine J McCleary, MD MPH
CONTACT
(617) 632-6729

Principal Investigator

Nadine J McCleary, MD MPH
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135
United States
Dana-Farber Cancer Instiute - Merrimack Valley
Methuen, Massachusetts, 01844
United States

Collaborators and Investigators

Sponsor: Nadine McCleary, MD, MPH

  • Nadine J McCleary, MD MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-03
Study Completion Date2025-07-30

Study Record Updates

Study Start Date2023-04-03
Study Completion Date2025-07-30

Terms related to this study

Keywords Provided by Researchers

  • Gastrointestinal Cancer
  • Hematologic Cancer
  • Thoracic Cancer

Additional Relevant MeSH Terms

  • Gastrointestinal Cancer
  • Hematologic Cancer
  • Thoracic Cancer